APOE and Hypertension: Previous evidence has associated treatment of hypertension, regardless of antihypertensive agent, with an exponential decrease in incident AD dementia risk and cognitive decline particularly among hypertensive APOE ε4 carriers, but not non-carriers [82, 83] which might suggest that the magnitude of cognitive benefit among ε4 carriers afforded by general blood pressure-lowering effects is larger and that the importance of other mechanistic differences between ARBs and ACE-Is may be reduced relative to those observed in ε4 non-carriers.